Organogenesis Holdings Inc. (NASDAQ:ORGO – Get Free Report) CEO Gary S. Gillheeney sold 55,615 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $3.36, for a total value of $186,866.40. Following the completion of the sale, the chief executive officer now directly owns 3,044,779 shares of the company’s stock, valued at $10,230,457.44. This represents a 1.79 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Organogenesis Stock Down 9.2 %
ORGO opened at $3.24 on Thursday. The firm has a market cap of $429.55 million, a P/E ratio of -54.00 and a beta of 1.73. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The business has a 50 day moving average price of $3.45 and a 200 day moving average price of $3.01. Organogenesis Holdings Inc. has a twelve month low of $2.16 and a twelve month high of $4.70.
Organogenesis (NASDAQ:ORGO – Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.11. The business had revenue of $115.18 million during the quarter, compared to analysts’ expectations of $109.59 million. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. During the same period in the previous year, the company earned $0.02 earnings per share. Research analysts forecast that Organogenesis Holdings Inc. will post -0.07 EPS for the current year.
Institutional Investors Weigh In On Organogenesis
About Organogenesis
Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.
Further Reading
- Five stocks we like better than Organogenesis
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- Insider Buying Explained: What Investors Need to Know
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- Investing in the High PE Growth Stocks
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.